FGF23 and secondary hyperparathyroidism: Our data suggest that FGF23 itself may not be a primary target for reducing vascular damage in CKD but rather support the concept that FGF23 portrays vascular pathology associated with a disordered mineral metabolism such as hyperphosphatemia, low levels of vitamin D and secondary hyperparathyroidism.